share_log

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A:Femasys公佈截至2024年9月30日的季度財務業績,並提供公司最新情況
美股SEC公告 ·  11/12 16:05

Moomoo AI 已提取核心訊息

Femasys Inc., a leading biomedical company, has filed an amended Form 8-K/A with the SEC to correct previously reported dates. The amendment, dated November 12, 2024, rectifies the 'Date of Report' and related references from August 12, 2024, to the correct date of November 12, 2024. Alongside this administrative correction, Femasys announced its financial results for the third quarter ended September 30, 2024. The company reported a significant increase in sales, primarily attributed to its FemaSeed and FemVue products, with sales rising by 127.1% to $554,908 compared to the same quarter in the previous year. However, the company also experienced an increase in research and development expenses and reported a net loss of $5,408,860 for the quarter. Despite the loss, Femasys highlighted several commercial milestones, including the launch of FemaSeed in the U.S. and Europe, strategic distribution partnerships, and regulatory approvals for its products. CEO Kathy Lee-Sepsick expressed optimism about the company's commercial progress and upcoming collaborations. The company's cash reserves are expected to fund operations into July 2025.
Femasys Inc., a leading biomedical company, has filed an amended Form 8-K/A with the SEC to correct previously reported dates. The amendment, dated November 12, 2024, rectifies the 'Date of Report' and related references from August 12, 2024, to the correct date of November 12, 2024. Alongside this administrative correction, Femasys announced its financial results for the third quarter ended September 30, 2024. The company reported a significant increase in sales, primarily attributed to its FemaSeed and FemVue products, with sales rising by 127.1% to $554,908 compared to the same quarter in the previous year. However, the company also experienced an increase in research and development expenses and reported a net loss of $5,408,860 for the quarter. Despite the loss, Femasys highlighted several commercial milestones, including the launch of FemaSeed in the U.S. and Europe, strategic distribution partnerships, and regulatory approvals for its products. CEO Kathy Lee-Sepsick expressed optimism about the company's commercial progress and upcoming collaborations. The company's cash reserves are expected to fund operations into July 2025.
生物醫藥領域領先企業Femasys Inc.已向美國證券交易委員會提交修訂後的8-K/A表格,以更正先前報告的日期。這份修訂稿日期爲2024年11月12日,糾正了「報告日期」及相關參考日期,從2024年8月12日更正爲正確的日期:2024年11月12日。除了這次行政糾正外,Femasys宣佈了截至2024年9月30日的第三季度財務業績。公司報告銷售額大幅增長,主要歸因於其FemaSeed和FemVue產品,銷售額較前一年同期增長了127.1%,達到554,908美元。然而,公司的研發支出也有所增加,報告該季度淨虧損爲5,408,860美元。儘管虧損,Femasys強調了幾個商業里程碑,包括在美國和歐洲推出FemaSeed、戰略分銷合作伙伴關係,以及對其產品的監管批准。首席執行官Kathy Lee-Sepsick表示對公司商業進展和即將到來的合作感到樂觀。公司的現金儲備預計可支撐到2025年7月。
生物醫藥領域領先企業Femasys Inc.已向美國證券交易委員會提交修訂後的8-K/A表格,以更正先前報告的日期。這份修訂稿日期爲2024年11月12日,糾正了「報告日期」及相關參考日期,從2024年8月12日更正爲正確的日期:2024年11月12日。除了這次行政糾正外,Femasys宣佈了截至2024年9月30日的第三季度財務業績。公司報告銷售額大幅增長,主要歸因於其FemaSeed和FemVue產品,銷售額較前一年同期增長了127.1%,達到554,908美元。然而,公司的研發支出也有所增加,報告該季度淨虧損爲5,408,860美元。儘管虧損,Femasys強調了幾個商業里程碑,包括在美國和歐洲推出FemaSeed、戰略分銷合作伙伴關係,以及對其產品的監管批准。首席執行官Kathy Lee-Sepsick表示對公司商業進展和即將到來的合作感到樂觀。公司的現金儲備預計可支撐到2025年7月。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息